Clinical Utility for Ion Endoluminal System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

365 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-29

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this prospective, multi-center, single-arm, clinical study is to evaluate the clinical utility and performance of the FDA-cleared Ion™ Endoluminal System ("Ion") for bronchoscopically approaching and facilitating the tissue sampling of pulmonary nodules.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

iNod™ Ultrasound-Guided Needle Biopsy System Study

NCT05804435

Solitary Pulmonary Nodule Multiple Pulmonary Nodules Biopsy, Fine-Needle

WITHDRAWN NA

Radial-Probe Endobronchial Ultrasound in Detecting Atelectasis in Patients Undergoing Peripheral Bronchoscopy

NCT03523689

Malignant Neoplasms of Respiratory and Intrathoracic Organs Lung Neoplasm

COMPLETED

Intra-op vs Pre-op Transbronchial Localization for Small Lung Nodule

NCT03793387

Lung Cancer

UNKNOWN NA

iNod System Human Feasibility Assessment

NCT02832284

Solitary Pulmonary Nodule Biopsy, Fine-Needle

COMPLETED NA

All in One Study: A Prospective Trial of Electromagnetic Navigation for Biopsy of Pulmonary Nodules

NCT03338049

Lung Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Nodule Lung Cancer Lung Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Robotic Bronchoscopy

The Ion™ Endoluminal System assists the user in navigating a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures. The Ion™ Endoluminal System enables fiducial marker placement. It does not make a diagnosis and is not for pediatric use.

Group Type OTHER

Ion Endoluminal System™

Intervention Type DEVICE

The Ion™ Endoluminal System, Model IF1000, is a software-controlled, electro-mechanical system designed to assist qualified physicians to navigate a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ion Endoluminal System™

The Ion™ Endoluminal System, Model IF1000, is a software-controlled, electro-mechanical system designed to assist qualified physicians to navigate a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 years and older
* Patient is suitable for elective bronchoscopy
* Patients with a moderate to high risk of lung cancer based on clinical, demographic and radiologic information or with suspected metastatic disease
* Solid or semi-solid pulmonary nodules of ≥ 1cm and ≤ 3cm in largest dimension
* Nodule is located in bronchial generation 4+ (i.e. beyond segmental bronchus\*
* Patients are candidates for CT-guided needle biopsy and/or surgical resection
* Patient able to understand and adhere to study requirements
* Patient able to understand and adhere to study requirements and able to provide informed consent
* Patient not legally incapacitated or in legal/court ordered institution
* Patients with no dependency on the investigator or sponsor

Exclusion Criteria

* Lack of fitness or exercise capacity to undergo bronchoscopy under general anesthesia as determined by physician prior to procedure
* Acute myocardial infarction or unstable angina ≤ 6 weeks prior to study procedure
* Clinically relevant partial trachea obstruction or obstruction of vena cava per physician assessment
* Acute respiratory failure, clinically significant hypoxemia, or high respiratory rate (i.e.\> 30 breaths per minute) per physician assessment)
* Renal insufficiency that presents risk per physician's discretion or liver failure (i.e. CHILD-PUGH Class C)
* World Health Organization functional Class III or Class IV Pulmonary Hypertension or history of clinically significant mPAP
* Lung abscess
* Known or suspected pregnancy
* Recent head injury (\<12 weeks pre-procedure) or subjects presenting with clinically significant neurologic deficits
* Unstable hemodynamic status (i.e. Dysrhythmia requiring intervention, altered mental status/consciousness)
* Subjects with pure ground glass opacity target nodule
* Inability to adequately oxygenate subject during procedure per physicians discretion (i.e. unable to achieve S02 \> 92% or requiring \>4L of oxygen prior to procedure)
* Subject with uncorrectable coagulopathy, bleeding or platelet disorders, history of major bleeding with bronchoscopy
* Subjects contraindicated for intubation or general anesthesia, or subjects with ASA ≥ 4
* Subjects taking antiplatelet (i.e. clopidogrel), anti-coagulant (i.e heparin or warfarin) or platelet aggression inhibitors (i.e. Abciximab or Eptifibatide) medications that cannot be stopped per standard practice, i.e. 5-7 days pre-procedure or heparin that cannot be held according to standard practice (6-12 hours). Aspirin not included.
* Any severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy (i.e. \>Stage 3 heart failure)
* Moderate-to-severe pulmonary fibrosis presenting procedural risk as assessed by physician
* Endobronchial lesion associated with lobar atelectasis
* Presence of bullae \>1cm located within a cone based trajectory of biopsy instruments or in location presenting risk per physician assessment
* Known allergy, sensitivity or previous allergic reaction to ortho-phthalaldehyde (OPA)
* Subjects taking the following medications: Immunosuppressive treatment with systemic azathioprine, Cyclosporine, antibodies or cytostatics, other chemotherapeutic agents or medications acting on immunophilins
* Non-systemic treatment for lung cancer (i.e. SBRT, ablation) performed in the same lobe as the target nodule(s)
* Previous surgical intervention (i.e. wedge resection or lobectomy) within the same lobe as target nodule (s)
* Participation in any interventional clinical study or clinical study with experimental agents or agents of unknown risk in last 30 days prior to screening

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No